Barbara McEowen Merrill

Title: Barbara McEowen Merrill: Innovator in Pharmaceutical Compounds

Introduction

Barbara McEowen Merrill is a distinguished inventor based in Durham, NC (US). She has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that interact with the granulocyte-colony stimulating factor receptor (G-CSFR). Her innovative work has the potential to impact treatments for patients with low white blood cell counts.

Latest Patents

Barbara holds a patent for "Compounds having affinity for the granulocyte-colony stimulating factor receptor (G-CSFR) and associated uses." This patent describes novel compounds that bind to G-CSFR, featuring a peptide chain approximately 6 to 40 amino acids in length. These compounds serve as useful probes for affinity screening and have demonstrated both agonist and antagonist activity for the G-CSFR. Consequently, they are valuable in treating diseases related to low white blood cell titer. Additionally, pharmaceutical compositions and methods of use are included in her patent.

Career Highlights

Barbara is currently associated with Affymax, Inc., where she continues to advance her research and development efforts. Her work is characterized by a commitment to innovation and a focus on improving patient outcomes through her discoveries.

Collaborations

Barbara has collaborated with notable colleagues, including Steven E Cwirla and Palani Balu. These partnerships have contributed to her success and the advancement of her research initiatives.

Conclusion

Barbara McEowen Merrill is a remarkable inventor whose work in pharmaceutical compounds showcases her dedication to innovation in healthcare. Her contributions have the potential to significantly improve treatment options for patients in need.